CA2841994C - C4b-binding protein (c4bp) isoforms for immunomodulation - Google Patents

C4b-binding protein (c4bp) isoforms for immunomodulation Download PDF

Info

Publication number
CA2841994C
CA2841994C CA2841994A CA2841994A CA2841994C CA 2841994 C CA2841994 C CA 2841994C CA 2841994 A CA2841994 A CA 2841994A CA 2841994 A CA2841994 A CA 2841994A CA 2841994 C CA2841994 C CA 2841994C
Authority
CA
Canada
Prior art keywords
autoimmune
disease
group
cells
c4bp
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2841994A
Other languages
English (en)
French (fr)
Other versions
CA2841994A1 (en
Inventor
Josep M. Aran Perramon
Rut Olivar Miro
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Fundacio Privada Institut dInvestigacio Biomedica de Bellvitge IDIBELL
Original Assignee
Fundacio Privada Institut dInvestigacio Biomedica de Bellvitge IDIBELL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fundacio Privada Institut dInvestigacio Biomedica de Bellvitge IDIBELL filed Critical Fundacio Privada Institut dInvestigacio Biomedica de Bellvitge IDIBELL
Publication of CA2841994A1 publication Critical patent/CA2841994A1/en
Application granted granted Critical
Publication of CA2841994C publication Critical patent/CA2841994C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/472—Complement proteins, e.g. anaphylatoxin, C3a, C5a
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/36—Skin; Hair; Nails; Sebaceous glands; Cerumen; Epidermis; Epithelial cells; Keratinocytes; Langerhans cells; Ectodermal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A61K38/1725—Complement proteins, e.g. anaphylatoxin, C3a or C5a
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/19—Dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/22—Immunosuppressive or immunotolerising
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/24—Antigen-presenting cells [APC]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/418—Antigens related to induction of tolerance to non-self
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0639—Dendritic cells, e.g. Langherhans cells in the epidermis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/998—Proteins not provided for elsewhere

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Dermatology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Transplantation (AREA)
  • Rheumatology (AREA)
CA2841994A 2011-07-15 2012-07-16 C4b-binding protein (c4bp) isoforms for immunomodulation Active CA2841994C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP11382240.7 2011-07-15
EP11382240A EP2557089A2 (en) 2011-07-15 2011-07-15 Compositions and methods for immunomodulation
PCT/EP2012/063932 WO2013010998A2 (en) 2011-07-15 2012-07-16 Compositions and methods for immunomodulation

Publications (2)

Publication Number Publication Date
CA2841994A1 CA2841994A1 (en) 2013-01-24
CA2841994C true CA2841994C (en) 2020-08-25

Family

ID=45563648

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2841994A Active CA2841994C (en) 2011-07-15 2012-07-16 C4b-binding protein (c4bp) isoforms for immunomodulation

Country Status (9)

Country Link
US (1) US10106589B2 (enExample)
EP (3) EP2557089A2 (enExample)
JP (2) JP6290078B2 (enExample)
AU (1) AU2012285852B2 (enExample)
CA (1) CA2841994C (enExample)
DK (1) DK2731963T3 (enExample)
ES (1) ES2581278T3 (enExample)
PL (1) PL2731963T3 (enExample)
WO (1) WO2013010998A2 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2557089A2 (en) * 2011-07-15 2013-02-13 Fundació Institut d'Investigació Biomèdica de Bellvitge (IDIBELL) Compositions and methods for immunomodulation
AU2014236778B2 (en) * 2013-03-14 2019-01-03 Baxalta GmbH Factor H for transplantation
US9724365B2 (en) 2013-11-18 2017-08-08 University of Pittsburgh—of the Commonwealth System of Higher Education Microsphere-based delivery and ex vivo manipulation of dendritic cells for autoimmune therapies
FR3018819A1 (fr) * 2014-03-19 2015-09-25 Univ Bourgogne Traitement de la reponse inflammatoire et dysimmunitaire
EP3384923A1 (en) 2017-04-06 2018-10-10 Fundació Institut d'Investigació Biomèdica de Bellvitge (IDIBELL) C4bp-based compounds for treating immunological diseases
EP3808763A1 (en) * 2019-10-17 2021-04-21 Fundació Institut d'Investigació Biomèdica de Bellvitge (IDIBELL) Compounds for immunomodulation
WO2025172510A1 (en) 2024-02-15 2025-08-21 Fundació Institut D'investigació Biomèdica De Bellvitge (Idibell) Compounds for treating diseases

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0742235B2 (ja) * 1985-11-08 1995-05-10 三共株式会社 自己免疫性疾病の予防・治療剤
EP0465633A1 (en) * 1990-01-26 1992-01-15 Biogen, Inc. C4 binding protein fusion proteins
EP1413587A2 (en) * 1991-05-03 2004-04-28 Washington University Modified complement system regulator
JPH07509133A (ja) 1992-07-17 1995-10-12 リボザイム・ファーマシューティカルズ・インコーポレイテッド 動物疾患の処置のための方法および剤
US6447796B1 (en) 1994-05-16 2002-09-10 The United States Of America As Represented By The Secretary Of The Army Sustained release hydrophobic bioactive PLGA microspheres
US5831068A (en) 1995-08-21 1998-11-03 Duke University Method to increase the density of antigen on antigen presenting cells
US5853719A (en) 1996-04-30 1998-12-29 Duke University Methods for treating cancers and pathogen infections using antigen-presenting cells loaded with RNA
US6395713B1 (en) 1997-07-23 2002-05-28 Ribozyme Pharmaceuticals, Inc. Compositions for the delivery of negatively charged molecules
EP1044021B1 (en) 1998-01-05 2009-09-23 The University of Washington Enhanced transport using membrane disruptive agents
WO2000053722A2 (en) 1999-03-10 2000-09-14 Phogen Limited Delivery of nucleic acids and proteins to cells
US20020130430A1 (en) 2000-12-29 2002-09-19 Castor Trevor Percival Methods for making polymer microspheres/nanospheres and encapsulating therapeutic proteins and other products
US20030077829A1 (en) 2001-04-30 2003-04-24 Protiva Biotherapeutics Inc.. Lipid-based formulations
US7060498B1 (en) 2001-11-28 2006-06-13 Genta Salus Llc Polycationic water soluble copolymer and method for transferring polyanionic macromolecules across biological barriers
US7141540B2 (en) 2001-11-30 2006-11-28 Genta Salus Llc Cyclodextrin grafted biocompatible amphilphilic polymer and methods of preparation and use thereof
CN100455600C (zh) * 2002-08-14 2009-01-28 阿维迪斯公司 包含支架,佐剂和抗原的异源多聚体化合物及其用途
WO2004020639A2 (en) * 2002-08-14 2004-03-11 Avidis Sa Production of multimeric fusion proteins using a c4bp scaffold
WO2005051414A1 (en) * 2003-11-26 2005-06-09 Avidis Sa Use of c4bp core region as a cd40 agonist
WO2005069726A2 (en) * 2004-01-21 2005-08-04 Case Western Reserve University Hybrid and chimeric polypeptides that regulate activation of complement
EP1790358A1 (en) * 2005-11-23 2007-05-30 Université de Reims Champagne-Ardennes Protein constructs designed for targeting and lysis of cells
GB0706912D0 (en) * 2007-04-10 2007-05-16 Isis Innovation Novel viral vaccines
US20090324585A1 (en) * 2008-06-12 2009-12-31 The Trustees of the Leland Standford Junior University Complement inhibitory agents as therapeutics in posttraumatic and degenerative arthritis
US8840868B2 (en) * 2009-02-04 2014-09-23 The Regents Of The University Of Colorado, A Body Corporate Non-invasive detection of complement-mediated inflammation using CR2-targeted nanoparticles
EP2557089A2 (en) * 2011-07-15 2013-02-13 Fundació Institut d'Investigació Biomèdica de Bellvitge (IDIBELL) Compositions and methods for immunomodulation

Also Published As

Publication number Publication date
JP2017221196A (ja) 2017-12-21
US10106589B2 (en) 2018-10-23
ES2581278T3 (es) 2016-09-05
EP2731963A2 (en) 2014-05-21
PL2731963T3 (pl) 2016-10-31
WO2013010998A3 (en) 2013-04-04
EP2731963B1 (en) 2016-04-13
DK2731963T3 (en) 2016-07-04
EP2557089A2 (en) 2013-02-13
EP3048111A1 (en) 2016-07-27
US20140309158A1 (en) 2014-10-16
AU2012285852A1 (en) 2014-02-06
JP6290078B2 (ja) 2018-03-07
AU2012285852B2 (en) 2017-04-13
WO2013010998A2 (en) 2013-01-24
JP2014523252A (ja) 2014-09-11
CA2841994A1 (en) 2013-01-24

Similar Documents

Publication Publication Date Title
CA2841994C (en) C4b-binding protein (c4bp) isoforms for immunomodulation
Jones et al. Immunosuppression by mesenchymal stromal cells: from culture to clinic
McDaid et al. Heme oxygenase‐1 modulates the allo‐immune response by promoting activation‐induced cell death of T cells
CN107849536B (zh) 用于得到调节性t细胞的方法及其用途
AU2010224172B2 (en) Treatment methods for autoimmune disorders
US20110150845A1 (en) Methods and compositions for modulating immunological tolerance
JP2015502135A (ja) 多発性硬化症の治療のためのａｐｃ媒介寛容誘導
JP7778070B2 (ja) 免疫調節のための化合物
Yang et al. Glucose-regulated protein 78-induced myeloid antigen-presenting cells maintained tolerogenic signature upon LPS stimulation
JP7637418B2 (ja) 胸腺再生およびｔ細胞再構成のための組成物および方法
JP2017516752A (ja) 単離されたドナーｍｈｃ由来ペプチド及びその使用
Holcmann et al. Skin inflammation is not sufficient to break tolerance induced against a novel antigen
KR102314158B1 (ko) 중간엽 줄기세포를 포함하는 지방 생성을 억제하기 위한 조성물
EP4496883A1 (en) Methods and products for culturing t cells and uses thereof
CN120019146A (zh) 通用t细胞和组合物及它们的使用方法
Goltsev et al. Immunoregulatory effect of mouse fetal neural cells on the graft-versus-host disease
Zhang Leading to Immune Tolerogenic DCs for Preventing Alloimmune Rejection
Curran Expansion of antigen specific regulatory T cells in an IDO expressing fibroblast co-culture
KR20230158102A (ko) 인간 식작용 세포의 생체외 증식
Mellor Indoleamine 2, 3 dioxygenase (IDO): a pivotal counter-regulatory switch at sites of inflammation
Scherjon MSC and the possible role in fetomaternal tolerance: a paradigm for transplantation tolerance
HK1240598B (zh) 用於诱导组织再生的肽及其应用
Sakuishi et al. NKT Cells in Multiple Sclerosis

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20170309